calendar
13,309 catalysts · 3,603 8k filing · 2,401 grant · 2,049 approval · 1,383 device 510k · 1,000 device adverse event · 931 device pma
13,309 catalysts · 3,603 8k filing · 2,401 grant · 2,049 approval · 1,383 device 510k · 1,000 device adverse event · 931 device pma
*HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 8mm x 8mm; Material Number (UPN): M00553530; — Reason: Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site. — Status: Ongoing
Alphenix INFX-8000V, interventional fluoroscopic x-ray system — Reason: It has been discovered that there is a possibility that the fixing screws of the ceiling movement gear in the ceiling suspended arm that are part of the X-ray interventional systems may become loose. As a result, ceiling lateral movement may no longer be possible, abnormal noise may be generated from the suspension system and a sensor error may be displayed — Status: Ongoing
AXIOS Stent and Electrocautery-Enhanced Delivery System - 8mm x 8mm; Material Number (UPN): M00553690; — Reason: Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site. — Status: Ongoing
Brand Name: Bisaf Strep A Self-Test. Test for detection of group A streptococcal antigens in throat swabs. — Reason: Product not cleared by the FDA. — Status: Ongoing
Brand Name: VOLT" Wrist Treatment System Product Name: 2.4/2.7 2Column Dist Radius Plate 6Hd/10Shaft/Left/Std/139mm Model/Catalog Number: 02.426.681S Product Description: 2 Column Distal Radius Plate - 6 Head, 10 Shaft, Standard Left - 139mm — Reason: The supplier manufactured anatomical left plates with an incorrect thread orientation. — Status: Ongoing
Alphenix INFX-8000C, interventional fluoroscopic x-ray system — Reason: It has been discovered that there is a possibility that the fixing screws of the ceiling movement gear in the ceiling suspended arm that are part of the X-ray interventional systems may become loose. As a result, ceiling lateral movement may no longer be possible, abnormal noise may be generated from the suspension system and a sensor error may be displayed — Status: Ongoing
NAEOTOM Alpha.Prime Software applications: syngo.CT Brain Quantification syngo.CT Vessel Hyperdensities syngo.CT ASPECTS — Reason: To remove the software applications from certain CT systems as the applications have not received FDA 510(k) clearance. — Status: Ongoing
Wondfo Streptococcal A At-Home Self-Test. At-home test for group A beta-hemolytic streptococcal infection. — Reason: Product not cleared by the FDA. — Status: Ongoing
DC grant. $134,109. PI: Megan Anne Kirchgessner
HL grant. $794,063. PI: JAMES S PANKOW
DK grant. $150,930. PI: Samantha Fortin
HL grant. $3,202,749. PI: Robyn Leagh McClelland
OD grant. $802,500. PI: Margaux Pinney
HL grant. $829,413. PI: NORRINA Bai ALLEN
HL grant. $697,200. PI: WENDY S POST
HL grant. $674,872. PI: KAROL E WATSON
HL grant. $505,956. PI: Alain Gerald Bertoni
CA grant. $897,500. PI: Jeffrey Michael Bethony
Sponsor: NOVO. Form: TABLET. Route: ORAL
Sponsor: VISTAPHARM LLC. Form: SOLUTION. Route: ORAL
Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Sponsor: CHARTWELL. Form: TABLET. Route: ORAL
Sponsor: PHARM ASSOC. Form: SYRUP. Route: ORAL
Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL
Sponsor: VISTAPHARM LLC. Form: TABLET. Route: ORAL
Sponsor: RISING. Form: INJECTABLE. Route: INJECTION
Sponsor: HIKMA. Form: SOLUTION. Route: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL
Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION
Sponsor: OZANTRI. Form: TABLET. Route: ORAL
Sponsor: UPSHER SMITH LABS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: SCPHARMACEUTICALS. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: RB HLTH. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL
Sponsor: WES PHARMA INC. Form: SOLUTION. Route: ORAL
Sponsor: GENUS. Form: TABLET. Route: ORAL
Sponsor: GENUS. Form: SOLUTION. Route: ORAL
Sponsor: HIKMA. Form: TABLET. Route: ORAL
Sponsor: HIKMA. Form: TABLET. Route: ORAL
Sponsor: PH HEALTH. Form: SOLUTION. Route: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL
Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL
Sponsor: ZYDUS PHARMS. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL
Sponsor: LGM PHARMA. Form: CAPSULE. Route: ORAL
Sponsor: PURACAP LABS BLU. Form: TABLET. Route: ORAL
Sponsor: CEPHALON. Form: TROCHE/LOZENGE. Route: TRANSMUCOSAL
Sponsor: HIKMA. Form: SPRAY, METERED. Route: NASAL
Sponsor: HIKMA. Form: SPRAY, METERED. Route: NASAL
Sponsor: WEST-WARD PHARMS INT. Form: INJECTABLE. Route: INJECTION